Treatment of COVID-19 Complications
TREATMENT OF COVID-19 COMPLICATIONS
The majority of people who have COVID-19 recover entirely within a few weeks. However, some people continue to experience symptoms after their initial recovery and the most common symptoms and causes include:
• Fatigue • Shortness of breath • Cough • Chest pain • Muscle pain • Fever • Sore throat • Loss of taste or smell • Damage to the lungs leading to long-term breathing problems.
The SARS-CoV-2 virus primarily affects the respiratory system and can cause life-threatening pneumonia. Studies show the disease attacks the respiratory system and affects multiple organs with blood clots and inflammation.
Almost 80% of COVID-19 infections are mild or asymptomatic, 15% are severe infections requiring oxygen, and 5% are critical infections requiring ventilation.
It is estimated that approximately one-third of people with COVID-19 had persistent symptoms as long as 9 months after infection. Many COVID-19 recovered patients are returning to doctors with conditions including breathlessness, cardiac, lung, and other complications.
It is estimated that approximately one-third of people with COVID-19 had persistent symptoms as long as 9 months after infection. Many COVID-19 recovered patients are returning to doctors with conditions including breathlessness, cardiac, lung, and other complications.
The COVID-19 pandemic has adversely impacted global public health and the international economy and millions of people are suffering from COVID-19 complications.
For this reason, there is an urgent need for effective therapy for the treatment of these symptoms. To date, numerous clinical trials have been filed in the USA to examine the safety and efficacy of mesenchymal stem cells and their exosomes for treating COVID-19 patients.
At PRMEDICA, the medical team has developed protocols to treat patients for the effects of COVID-19 complications. Several clinical studies have been conducted on SARS-CoV-2 positive patients using mesenchymal stem cells and MSC-derived exosomes, with promising results link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224671/.
Mesenchymal stem cells can modulate the proliferation, activation, and effector function of all immune cells that play an essential role in the pathogenesis of acute and chronic inflammatory lung diseases. PRMEDICA has developed protocols using cord tissue-derived mesenchymal stem cells and optimal-purity, isolated MSC-derived exosomes to successfully treat respiratory system complications for patients recovering from COVID-19.
For this reason, there is an urgent need for effective therapy for the treatment of these symptoms. To date, numerous clinical trials have been filed in the USA to examine the safety and efficacy of mesenchymal stem cells and their exosomes for treating COVID-19 patients.
At PRMEDICA, the medical team has developed protocols to treat patients for the effects of COVID-19 complications. Several clinical studies have been conducted on SARS-CoV-2 positive patients using mesenchymal stem cells and MSC-derived exosomes, with promising results link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224671/.
Mesenchymal stem cells can modulate the proliferation, activation, and effector function of all immune cells that play an essential role in the pathogenesis of acute and chronic inflammatory lung diseases. PRMEDICA has developed protocols using cord tissue-derived mesenchymal stem cells and optimal-purity, isolated MSC-derived exosomes to successfully treat respiratory system complications for patients recovering from COVID-19.
PRMEDICA protocol for the treatment of Respiratory System Complications.
- 1. The patient requires the following studies:
- a. Bloodwork panel with cancer markers
- b. Chest X-Ray or CT scan
- c. General Spirometry studies
- 2. After the patient is diagnosed, the attending doctor determines the number of stem cells and exosomes to be applied, depending on the patient´s weight and the severity of the condition.
PROCEDURE:
- 2 x Simple nebulization (saline solution) (One before stem cell/exosome nebulization and one after)
- 3 x IV Ozone (apply the same day as the nebulization)
- 1 x nebulization with 10 million stem cells and 3 ml exosomes
- 1 x IV infusion of up to 200 million stem cells and 10 ml exosomes.
- 3 x Hyperbaric Oxygen therapy.
Contact PRMEDICA for further information about Nebulized and Intravenous Stem Cell Therapy for the treatment of Lung Disease and other COVID-19 related complications.
CONTACT:
624 688 8497 | 624 157 1970
info@prmedica-inc.com
CORPORATE HEADQUARTERS MEXICO
Carretera Transpeninsular Km 25
Plaza Esperanza
Cerro Colorado,San José del Cabo
(Next to Fresko) BCS Mexico 23400
Also in News
Aneurysms: The Silent Killers
Abdominal aortic aneurysms are silent killers that show little or no symptoms of the condition at all.
Post-COVID-19 Complications and Treatments
The medical experts at PRMEDICA have developed advanced protocols to treat patients that have suffered from COVID-19 complications, and many of these patients are experiencing very positive results.
Breakthrough Stem Cell Treatments For Children With Autism
For the past 10 years PRMEDICA has been at the forefront of Biocellular Regenerative Medicine and is widely recognized as one of the world leaders in the field of Biocellular Therapies.